DVA.V - Delivra Corp.

TSXV - TSXV Delayed Price. Currency in CAD
0.3000
0.0000 (0.00%)
At close: 2:11PM EST
Stock chart is not supported by your current browser
Previous Close0.3000
Open0.3000
Bid0.28 x 0
Ask0.36 x 0
Day's Range0.3000 - 0.3000
52 Week Range0.2900 - 0.5900
Volume25,000
Avg. Volume38,458
Market Cap14.244M
Beta (3Y Monthly)-2.64
PE Ratio (TTM)N/A
EPS (TTM)-0.04
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE3 days ago

    Today's Research Reports on Delivra, Copper Mountain Mining, Ballard Power Systems and Pattern Energy

    NEW YORK, NY / ACCESSWIRE / December 14, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

  • Baystreet6 days ago

    Stocks in play: Delivra Corp.

    Announced the publication of positive data from a pre-clinical study demonstrating the safety and efficacy ...

  • CNW Group6 days ago

    Delivra publishes positive results using its platform technology for topical Advil™ (ibuprofen) and Celebrex™ (celecoxib)

    TORONTO, Dec. 11, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") today announced the publication of positive data from a pre-clinical study demonstrating the safety and efficacy to treat pain directly with a topical version of Advil™ (ibuprofen) and Celebrex™ (celecoxib). In pre-clinical testing, undertaken by an independent third-party research organization, the Delivra-ibuprofen and Delivra-celecoxib formulations provided sustained pain reduction. In the study, both Delivra formulations were tested in an acute dog model of arthritis where the formulation performed equally or better for swelling and pain reduction compared its oral equivalent and test controls.

  • CNW Group20 days ago

    View from the C-Suite: Dr. Joseph Gabriele, Chief Executive Officer, Delivra Corp., tells his company's story. Filmed on November 27, 2018

    TORONTO , Nov. 27, 2018 /CNW/ -   https://www.youtube.com/watch?v=xIkuz0mNwPY The View from the C-Suite video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange ...

  • CNW Group28 days ago

    Delivra Achieves Record Third Quarter 2018 Revenues

    TORONTO, Nov. 19, 2018  /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") reported its financial results for the three and nine months ended September 30, 2018. Delivra's financial statements are prepared in accordance with International Financial Reporting Standards.

  • CNW Group2 months ago

    Ernst & Young Names Dr. Joseph Gabriele of Delivra - Entrepreneur of the Year 2018 Ontario Award in the Health Care Category

    TORONTO, Oct. 30, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company"), a science and biotechnology company, today announced that its Founder and CEO, Dr. Joseph Gabriele, is the recipient of the Ernst & Young Entrepreneur Of The Year 2018 Ontario award in the Health Care category. "I'm humbled and honoured by the award", said Joseph Gabriele.

  • CNW Group2 months ago

    Delivra Announces Stock Option Grant and Postponement of Warrant Expiry

    TORONTO, Oct. 15, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company"), a scientific and biotechnology company, today announced that it has issued an aggregate of 550,000 incentive stock options (the "Options") each exercisable into one common share in the capital of the Company, to eligible participants under the Company's incentive stock option plan (the "Plan"). The Company also makes reference to the 700,000 share purchase warrants, exerciseable between $0.60 and $0.61 per share, expiring on October 31, 2018. Pursuant to the terms of the warrants, the warrant expiry date has been postponed until the third business day following the lifting of the "blackout period" that will be in effect on October 31, 2018 in connection with the release of the Company's September 30th, 2018 financial results.

  • Simply Wall St.2 months ago

    Who Owns Delivra Corp (CVE:DVA)?

    A look at the shareholders of Delivra Corp (CVE:DVA) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning Read More...

  • CNW Group3 months ago

    Delivra Receiving Interest for its Expertise and Technology for Use in the Cannabis and Pharma Industries

    TORONTO, Oct. 1, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company"), a scientific and biotechnology company, today announced that it has recently received inquiries from a number of interested parties in relation to the Company's proprietary transdermal delivery system platform, including its proprietary applications for the cannabis and pharma industries. As a result of these inquiries, the Company has engaged Canaccord Genuity Corp. to act as exclusive financial advisor to identify, review, analyze and explore the range of strategic and other opportunities available to the Company within the cannabis and pharma industries. There can be no assurance that the Company will enter into any transaction, that there will be any change in the operation or ownership of the Company, or that the Company will take any other corporate action as a result of the review.

  • CNW Group4 months ago

    Delivra announces appointment of Chief Financial Officer

    TORONTO, Aug. 27, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") today announces the appointment of Pascal Attard as the Company's Chief Financial Officer. Mr. Attard has been with the Company since June 2015. For the past two years, Mr. Attard served as the Company's Vice-President, Finance and prior to that, was the Company's Controller.

  • CNW Group4 months ago

    Delivra achieves record second quarter 2018 results

    TORONTO, Aug. 20, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") reported its financial results for the three and six months ended June 30, 2018. Delivra's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").

  • Baystreet7 months ago

    Stocks in play: Delivra Corp.

    Reported its financial results for the three months ended March 31, 2018. Revenues came in at $995,938,000, ...

  • CNW Group7 months ago

    Delivra Announces First Quarter Financial Results

    TORONTO, May 22, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") reported its financial results for the three months ended March 31, 2018. Delivra's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").

  • CNW Group7 months ago

    Delivra Exposes that the Cannabis Market Requires Further Standardization and Rigourous Testing

    TORONTO, May 3, 2018 /CNW/ - Delivra Corp. ("Delivra", or "the Company") today announced the publication of their analytical evaluation of a variety of third-party over-the-counter hemp consumer products for tetrahydrocannabinol ("THC") and cannabidiol ("CBD") content to further develop its internal expertise and evaluate the consumer landscape. The publication conducted out of Delivra's research lab in Charlottetown, PEI and partially funded by Skills-PEI and by the Atlantic Canada Opportunities Agency, concluded that most third-party consumer products met the federal guidelines on THC content. As a tool, the testing method is amenable to a variety of consumer products indicating its general applicability towards cannabis oils and more complex materials like creams and edibles.

  • ACCESSWIRE8 months ago

    Today’s Research Reports on Annidis, RNC Minerals, Delivra and The Hydropothecary

    NEW YORK, NY / ACCESSWIRE / April 26, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • CNW Group8 months ago

    Delivra's Successful Product Development Strategy Yields Product Line Expansions - Including Cannabis-Related Products

    TORONTO, April 26, 2018 /CNW/ - Delivra Corp. ("Delivra", or "the Company") today announced that its R&D, pre-clinical and clinical teams have successfully developed and tested line-extension products using its precision topical delivery system platform, DelivraTM. With the assistance and support of Emergence, Canada's virtual incubator that supports the growth of innovative bioscience and food sector ventures, Delivra has developed its strategy and executed on ready to use products for OTC line extensions that will compliment its already existing successful LivRelief products, and is ready for the upcoming legalization of cannabis with its vast array of cannabis-related products for third party distributors for different disease indications. This acceleration of LivRelief sales growth in the topical OTC category will involve additional unique SKUs at existing accounts and an enhancement of the distribution channels, which is now over 5,200 pharmacy/grocery and natural products stores.

  • Baystreet8 months ago

    Stocks in play: Delivra Corp.

    Announced the ability to treat pain directly with a topical version of Advil™ (ibuprofen). Testing for ...

  • CNW Group8 months ago

    Delivra successfully demonstrates targeted pain relief with topical ibuprofen

    TORONTO, April 24, 2018 /CNW/ - Delivra Corp. ("Delivra", or "the Company") today announced the ability to treat pain directly with a topical version of Advil™ (ibuprofen). In pre-clinical testing, undertaken by an independent third-party research organization, the Delivra-ibuprofen formulation provided sustained pain reduction. In the study, Delivra-ibuprofen was tested in an acute canine model of arthritis where the formulation performed equally or better for swelling and pain reduction compared its oral equivalent and test controls.

  • CNW Group8 months ago

    Delivra Publishes Pivotal Results on the Cholesterol & Lipid Lowering Agent Berberine

    TORONTO, April 18, 2018 /CNW/ - Delivra Corp. ("Delivra", or "the Company") today announced the publication of positive data from a pre-clinical study demonstrating the safety and greater bioavailability of transdermal berberine and dihydroberberine (DHB) for the prevention and treatment of cardiovascular disease related to high cholesterol and triglyceride levels. "This promising data supports Delivra's research and proprietary development of topical berberine and DHB's effectiveness to successfully reduce cholesterol and triglyceride levels. In certain cases, this treatment may provide a natural alternative to the use of statin drugs.

  • Baystreet8 months ago

    Stocks in play: Delivra Corp.

    Reported its financial results for the 12 months ended December 31, 2017. The company reported record ...

  • CNW Group8 months ago

    Delivra announces 20% sales growth for 2017

    TORONTO , April 10, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") reported its financial results for the three and twelve months ended December 31, 2017 . All ...

  • CNW Group8 months ago

    Delivra Corp. Completes $1,246,498.20 Non-Brokered Financing

    TORONTO, April 5, 2018 /CNW/ - Delivra Corp. (TSXV:DVA.V - News) (the "Company" or "Delivra") has completed a non-brokered private placement through the issuance of 3,561,423 units ("Units", as defined below) of the Company for gross proceeds of $1,246,498.20 (the "Offering"). Each Unit consists of one common share of the Company (a "Share") and one share purchase warrant (a "Warrant"). Each whole Warrant will entitle the holder to purchase one Share at a price of $0.50 per Share for 24 months from the date of closing, subject to the option of the Company, in the event that the closing price of Shares on the TSX Venture Exchange (the "TSXV") equals or exceeds $0.90 per Share for 10 consecutive days, to accelerate the expiry of the Warrants to 30 days after acceleration notice (the "Acceleration Option").

  • ACCESSWIRE9 months ago

    Today’s Research Reports on RNC Minerals, Delivra, The Hydropothecary and VentriPoint Diagnostics

    NEW YORK, NY / ACCESSWIRE / March 28, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRE10 months ago

    Canadian Exchanges Stock Scanner Maple Leaf Green World GreenSpace Brands Naturally Splendid Enterprises and Delivra

    LONDON, UK / ACCESSWIRE / February 15, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Consumer-Packaged Goods industry: Maple Leaf Green ...

  • CNW Group10 months ago

    Delivra Signs Distribution Agreement With NKS Health for Ready to Market Compounded Finished Products to Medical Doctors

    TORONTO, Feb. 1, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") announced today that it has signed a non-exclusive distribution agreement with NKS Health Ltd. ("NKS"), granting NKS the right to compound, distribute, promote, market and sell new unique pharmaceutical compounded product formulas developed by Delivra. The goal of the agreement is to build a partnership to both grow awareness and increase volume of sales for the Company's pharmaceutical pipeline. NKS will promote Delivra's cream-base therapeutics to physicians, hospitals and clinics in Canada through its network.  Delivra has developed a suite of compounded products for pain, anxiety and diabetic foot ulcers.